Utah Medical Products (UTMD) Fundamental Analysis: Revenue, Earnings & Valuation

8.63 / 10

Outperform

Fundamentals rate Outperform with an 8.6/10 score. Key strengths include high ROA (7.13%), profit‑margin (9.51%), cash‑to‑market (0.02) and profit‑to‑market ratios. Weak spots are negative EBIT/Revenue and low Asset‑to‑market, but overall metrics remain strong.

Analysis Checks(8/10)

Revenue-MV

Value-0.11

Score2/3

Weight8.59%

1M Return1.21%

ROA (%)

Value7.13

Score3/3

Weight14.87%

1M Return1.81%

Net cash flow from operating activities / Operating revenue (%)

Value38.05

Score3/3

Weight13.71%

1M Return1.63%

Profit-MV

Value-0.71

Score2/3

Weight25.55%

1M Return3.09%

Annualized net profit margin on total assets (%)

Value9.51

Score3/3

Weight14.87%

1M Return1.81%

EBIT / Total operating revenue (%)

Value-3027.80

Score0/3

Weight-29.96%

1M Return-5.19%

Asset-MV

Value-0.55

Score1/3

Weight2.73%

1M Return0.38%

Net profit / Total operating revenue (%)

Value29.58

Score2/3

Weight10.12%

1M Return1.26%

Cash-MV

Value0.02

Score3/3

Weight25.49%

1M Return2.92%

Net profit / Total profit (%)

Value79.24

Score3/3

Weight14.03%

1M Return1.76%

Is UTMD undervalued or overvalued?

UTMD scores 8.63/10 on fundamentals and holds a Discounted valuation at present. Backed by its 9.54% ROE, 29.30% net margin, 17.37 P/E ratio, 1.64 P/B ratio, and -12.12% earnings growth, these metrics solidify its Outperform investment rating.